Erasca Announces Proposed Public Offering of $150 Million of Common Stock

Core Viewpoint - Erasca, Inc. plans to offer and sell $150 million of its common stock in a proposed underwritten public offering, with an additional option for underwriters to purchase up to $22.5 million more [1][2] Group 1: Offering Details - The proposed public offering is subject to market and other conditions, and there is no assurance regarding its completion or the actual size and terms [1] - The offering is being conducted under a shelf registration statement on Form S-3, which was declared effective on August 22, 2025 [3] Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash and marketable securities, will be used to fund research and development of product candidates, other development programs, and for general corporate purposes [2] Group 3: Company Overview - Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company aims to develop novel therapies and combination regimens to comprehensively target the RAS/MAPK pathway in cancer treatment [5]